CN116035983A - 五味子和沙棘组合物的超临界co2提取方法及其应用 - Google Patents
五味子和沙棘组合物的超临界co2提取方法及其应用 Download PDFInfo
- Publication number
- CN116035983A CN116035983A CN202310180573.6A CN202310180573A CN116035983A CN 116035983 A CN116035983 A CN 116035983A CN 202310180573 A CN202310180573 A CN 202310180573A CN 116035983 A CN116035983 A CN 116035983A
- Authority
- CN
- China
- Prior art keywords
- supercritical
- extraction
- sea buckthorn
- schisandra chinensis
- shizandra berry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000605 extraction Methods 0.000 title claims abstract description 62
- 235000003145 Hippophae rhamnoides Nutrition 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 235000021028 berry Nutrition 0.000 title claims abstract description 22
- 240000000950 Hippophae rhamnoides Species 0.000 title description 4
- 241000229143 Hippophae Species 0.000 claims abstract description 62
- 239000000284 extract Substances 0.000 claims abstract description 36
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 32
- 235000003935 Hippophae Nutrition 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 22
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 14
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 14
- 102000003777 Interleukin-1 beta Human genes 0.000 claims abstract description 8
- 108090000193 Interleukin-1 beta Proteins 0.000 claims abstract description 8
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 7
- 229940055019 propionibacterium acne Drugs 0.000 claims abstract description 7
- 230000028327 secretion Effects 0.000 claims abstract description 7
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 241000736075 Schisandra Species 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 241000219100 Rhamnaceae Species 0.000 claims description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000005642 Oleic acid Substances 0.000 claims description 5
- 235000021314 Palmitic acid Nutrition 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 5
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
- 235000020778 linoleic acid Nutrition 0.000 claims description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 5
- 229960004488 linolenic acid Drugs 0.000 claims description 5
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- 235000021313 oleic acid Nutrition 0.000 claims description 5
- 230000003068 static effect Effects 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 229940111134 coxibs Drugs 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract description 28
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 14
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 11
- 229930195729 fatty acid Natural products 0.000 abstract description 11
- 239000000194 fatty acid Substances 0.000 abstract description 11
- 150000004665 fatty acids Chemical class 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000000194 supercritical-fluid extraction Methods 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 14
- 239000012224 working solution Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229960000590 celecoxib Drugs 0.000 description 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241001117772 Elaeagnaceae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HTBWBWWADZJXID-TXEJJXNPSA-N Wuweizisu C Chemical compound COC1=C2C=3C(OC)=C4OCOC4=CC=3C[C@H](C)[C@H](C)CC2=CC2=C1OCO2 HTBWBWWADZJXID-TXEJJXNPSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000658 coextraction Methods 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000024346 drought recovery Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- HTBWBWWADZJXID-UHFFFAOYSA-N gamma-schisandrin Natural products COC1=C2C=3C(OC)=C4OCOC4=CC=3CC(C)C(C)CC2=CC2=C1OCO2 HTBWBWWADZJXID-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了五味子和沙棘组合物的超临界CO2提取方法及其应用，该提取方法包括将五味子和沙棘粉末混合后进行超临界CO2提取处理，得到五味子‑沙棘超临界提取物。本发明通过将五味子与沙棘复配，并对其进行超临界CO2法提取，使五味子与沙棘中的脂肪酸大量提取出来，获得了相较于现有技术更好的提取效果。经试验证明，通过本发明的超临界提取方法获得的提取物具有更好的抗炎功效，能够有效抑制COX‑2表达、痤疮丙酸杆菌诱导的炎症以及炎症因子IL‑1β分泌。
Description
技术领域
本发明涉及植物提取技术领域，具体而言，涉及五味子和沙棘组合物的超临界CO2提取方法及其应用。
背景技术
沙棘(拉丁学名：Hippophae rhamnoides Linn.)，是一种胡颓子科、沙棘属落叶性灌木，其特性是耐旱、抗风沙，可以在盐碱化土地上生存，因此被广泛用于水土保持。中国西北部大量种植沙棘，用于沙漠绿化。沙棘果油含有类胡萝卜素、类黄酮和维生素E、维生素A，以及多种微量元素，如硒、镁、锌、铁、锰等。沙棘果油可促进面部微血管的循环，可有效地去除面部色斑、皱纹，起到滋润、美白、祛斑、除皱等多方面效果；还有一定的抗辐射作用和防治烫伤及冻伤的作用，降低感染。
五味子为木兰科植物五味子Schisandra chinensis(Turcz.)Baill.的干燥成熟果实。其果含有五味子素(Schisandrin C23H32O6)、维生素C、树脂、鞣质及少量糖类。有敛肺止咳、滋补涩精、止泻止汗之效。其叶、果实可提取芳香油。
现有研究多为五味子/沙棘分别在抗炎方面的技术，而对于五味子和沙棘组合物还未有报道。鉴于此，特提出本发明。
发明内容
本发明的目的在于提供一种五味子和沙棘组合物的超临界CO2提取方法及其应用。
五味子果油和沙棘籽油含有多种脂肪酸，而脂肪酸具有抗炎功效，为了提高五味子果油和沙棘籽油提取物中的脂肪酸含量，发明人创造性地将五味子和沙棘复配进行超临界CO2提取，并通过优化提取工艺，获得了脂肪酸含量显著提升的超临界提取物。将超临界提取物进行抗炎功能验证，试验结果证明，本发明的五味子和沙棘复配超临界提取物不仅能有效抑制COX-2表达，还能抵抗痤疮丙酸杆菌诱导的炎症以及降低炎症因子IL-1β含量。因此本发明的五味子和沙棘复配超临界提取物可以作为具有抗炎功效的化妆品原料，其在化妆品领域具有良好的应用前景。
本发明是这样实现的：
第一方面，本发明提供了一种五味子和沙棘组合物的超临界CO2提取方法，其包括将五味子和沙棘粉末混合后进行超临界CO2提取处理，得到五味子-沙棘超临界提取物；
上述五味子和沙棘粉末中五味子和沙棘的投料比为(1-3)：(1-3)。
通过大量试验发现，五味子和沙棘粉末复配的投料比对超临界提取物中脂肪酸含量有重要影响，而当五味子和沙棘的投料比为(1-3)：(1-3)时，超临界提取物中脂肪酸含量更高。
在一些实施例中，上述超临界CO2提取处理的条件为：提取压力为150-250bar，提取温度为35-45℃，提取时间为80-100min，CO2的流速为4-6mL/min。
在一些实施例中，提取时间为：动态提取10min→静态提取10min→动态提取10min，循环3次。
在一些实施例中，超临界CO2提取处理的夹带剂为乙醇。
在一些实施例中，夹带剂的流速为0.5-2mL/min。
在一些实施例中，夹带剂与CO2的流量比为1:(4-6)。
在一些实施例中，五味子和沙棘粉末是通过粉碎处理后获得的20-50目粉末。
第二方面，本发明提供了一种五味子-沙棘超临界提取物，该五味子-沙棘超临界提取物通过上述五味子和沙棘组合物的超临界CO2提取方法制备得到。
在一些实施例中，五味子-沙棘超临界提取物中包括棕榈酸、硬脂酸、油酸、亚油酸和亚麻酸。
在一些实施例中，上述五味子-沙棘超临界提取物中棕榈酸≥28.91mg/g，硬脂酸≥8.87mg/g，油酸≥54.90mg/g，亚油酸≥314.36mg/g，亚麻酸≥79.35mg/g。
第三方面，本发明提供了上述五味子-沙棘超临界提取物在制备抗炎产品中的应用。
在本发明中，抗炎产品可以是抗炎药物、抗炎化妆品、抗炎日用品或抗炎食品。
第四方面，本发明提供了上述五味子-沙棘超临界提取物在制备COX-2抑制剂中的应用。
第五方面，本发明提供了上述五味子-沙棘超临界提取物在制备抑制痤疮丙酸杆菌诱导的炎症的产品中的应用。
第六方面，本发明提供了上述五味子-沙棘超临界提取物在制备抑制炎症因子IL-1β分泌的产品中的应用。
本发明具有以下有益效果：
本发明通过将五味子与沙棘复配，并对其进行超临界CO2法提取，使五味子与沙棘中的脂肪酸大量提取出来，获得了相较于现有技术更高的提取效果。经试验证明，通过超临界提取获得的提取物具有更好的抗炎功效，能够有效抑制COX-2表达、痤疮丙酸杆菌诱导的炎症以及炎症因子IL-1β分泌。
附图说明
为了更清楚地说明本发明实施例的技术方案，下面将对实施例中所需要使用的附图作简单地介绍，应当理解，以下附图仅示出了本发明的某些实施例，因此不应被看作是对范围的限定，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据这些附图获得其他相关的附图。
图1为实验例1中的37种脂肪酸甲酯混标图谱。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚，下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者，按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者，均为可以通过市售购买获得的常规产品。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1
本实施例提供了一种五味子和沙棘组合物的超临界CO2提取方法，包括以下步骤：
(1)将五味子和沙棘干燥后进行粉碎处理，得到20目粉末。
(2)按照投料比为1:1的比例分别称取五味子和沙棘粉末，总计10g。
(3)将混合粉末、夹带剂乙醇添加至超临界CO2提取设备中进行提取，提取的条件为：
提取釜温度：40℃，提取压力：200bar，提取时间：动态提取10min→静态提取10min→动态提取10min。循环3次，共计90min。
CO2流速：5mL/min，夹带剂流速：1mL/min，夹带剂与CO2流量比：1:5，冲洗剂：乙醇，冲洗剂流速：0.5mL/min。
实施例2
本实施例提供了一种五味子和沙棘组合物的超临界CO2提取方法，包括以下步骤：
(1)将五味子和沙棘干燥后进行粉碎处理，得到20目粉末。
(2)按照投料比为1:3的比例分别称取五味子和沙棘粉末，总计10g。
(3)将五味子和沙棘粉末混合后添加至超临界CO2提取设备中进行提取，夹带剂为乙醇，提取的条件为：
提取釜温度：40℃，提取压力：200bar，提取时间：动态提取10min→静态提取10min→动态提取10min。循环3次，共计90min。
CO2流速：5mL/min，夹带剂流速：1mL/min，夹带剂与CO2流量比：1:5，冲洗剂：乙醇，冲洗剂流速：0.5mL/min。
实施例3
本实施例提供了一种五味子和沙棘组合物的超临界CO2提取方法，包括以下步骤：
(1)将五味子和沙棘干燥后进行粉碎处理，得到20目粉末。
(2)按照投料比为3:1的比例分别称取五味子和沙棘粉末，总计10g。
(3)将五味子和沙棘粉末混合后添加至超临界CO2提取设备中进行提取，夹带剂为乙醇，提取的条件为：
提取釜温度：40℃，提取压力：200bar，提取时间：动态提取10min→静态提取10min→动态提取10min。循环3次，共计90min。
CO2流速：5mL/min，夹带剂流速：1mL/min，夹带剂与CO2流量比：1:5，冲洗剂：乙醇，冲洗剂流速：0.5mL/min。
对比例1
与实施例1的区别在于，提取原料为总质量为10g的五味子。
对比例2
与实施例1的区别在于，提取原料为总质量为10g的沙棘。
对比例3
与实施例1的区别在于，五味子和沙棘粉末的投料比为1:5。
对比例4
与实施例1的区别在于，五味子和沙棘粉末的投料比为5:1。
对比例5
本对比例的五味子和沙棘超的临界CO2提取方法包括以下步骤：
(1)将五味子和沙棘干燥后进行粉碎处理，得到20目粉末。
(2)按照投料比为1:1的比例分别称取五味子和沙棘粉末，总计10g。
(3)将五味子和沙棘粉末分别添加至超临界CO2提取设备中进行提取，提取的条件同实施例1。
实验例1
采用气相色谱-质谱联用，检测实施例1-3与对比例1-5不同工艺下五味子-沙棘组合物的脂肪酸含量，具体步骤如下：
精确取样70μL于试管中，加入2％ NaOH-CH3OH溶液700μL，充分震荡后在60℃水浴反应30min，直至油滴彻底消失。然后加入14％BF3-CH3OH溶液700μL，在通风橱中80℃水浴5min后取出，自然冷却至室温，加入2.0mL正己烷充分震荡提取，静置待其分层，取上层有机相到50mL离心管中备用。采用安捷伦7890B-5977A气相色谱-质谱联用仪，DB-Fast FAME色谱柱(60m×0.250mm,0.25μm)进行GC-MS检测。图1为37种脂肪酸甲酯混标图谱。
表1实施例1-3与对比例1-5提取的脂肪酸含量
从表1的数据中可以看出，经过五味子与沙棘复配后的实施例1-3提取的脂肪酸含量显著高于单独成分提取的对比例1-2以及分开提取的对比例5，并且通过实施例1-3与对比例3-4相比，可以发现投料比对提取效果具有重要影响，当五味子与沙棘为(1-3)：(1-3)时提取效果更佳，其中棕榈酸≥28.91mg/g，硬脂酸≥8.87mg/g，油酸≥54.90mg/g，亚油酸≥314.36mg/g，亚麻酸≥79.35mg/g。
实验例2
采用COX-2体外抑制实验，检测不同工艺下五味子-沙棘组合物的抗炎功效，步骤如下：
用COX-2试剂盒测试不同样品对COX-2的抑制率，具体操作根据厂家提供的使用说明：
(1)配制样品培养基：将样品用DMSO稀释至待测浓度(100μg/mL)。
(2)试剂配制：
a.融解除rhCOX-2以外的其它所有试剂至室温，略离心使溶液沉淀至管底，再混匀备用。COX-2Probe、COX-2Cofactor(50X)和COX-2 Substrate(50X)配制在DMSO中，可37℃水浴0.5-2min促进融解。使用完毕后宜立即-20℃避光保存。
b.COX-2Cofactor工作液的配制：按照每个样品需要5微升COX-2Cofactor工作液的比例配制适量的COX-2Cofactor工作液。取适量的COX-2Cofactor(50X)，按照1:49的比例用COX-2Assay Buffer稀释。例如4微升COX-2Cofactor(50X)加入196微升COX-2AssayBuffer配制成200微升COX-2Cofactor工作液。配制好的COX-2Cofactor工作液可4℃存放，仅限当日使用。
c.COX-2工作液的配制：按照每个样品需5微升COX-2工作液的比例配制适量的COX-2工作液。取适量的rhCOX-2(25X)，按照1:24的比例用COX-2 Assay Buffer稀释。例如8微升rhCOX-2(25X)加入192微升COX-2 Assay Buffer配制成200微升COX-2工作液。配制好的COX-2工作液可在冰浴上暂时保存，1小时内酶活性基本稳定。注：所有涉及COX-2的操作应在冰上进行。
d.COX-2 Substrate工作液的配制：按照每个样品需5微升COX-2 Substrate工作液的比例配制适量的COX-2 Substrate工作液。取适量的COX-2 Substrate(50X)，加入等体积的Substrate Buffer，充分涡旋混匀，该混合物再按照1:24的比例用Milli-Q级纯水或重蒸水稀释，充分涡旋混匀。例如20微升COX-2 Substrate(50X)加入20微升SubstrateBuffer，涡旋混匀后，再加入960微升Milli-Q级纯水或重蒸水，再充分涡旋混匀，最终获得1毫升COX-2 Substrate工作液。配制好的COX-2 Substrate工作液可在冰浴上暂时保存，1小时内较为稳定。注：COX-2 Substrate工作液也可在样品检测时37℃孵育10分钟的过程中配制。
e.阳性抑制剂Celecoxib溶液的配制：本试剂盒提供的阳性对照抑制剂Celecoxib浓度为100μM，配制在DMSO中，可以根据需要使用与待测抑制剂一样的溶剂稀释成所需浓度或浓度梯度。通常Celecoxib的IC50约为10nM-100nM。
(3)样品检测：
a.参考表3.1，使用96孔黑板设置对照孔和样品孔，并按照下表依次加入样品和各溶液。加入待测样品后，混匀，37℃孵育10分钟。
表2试剂配比表
注：*样品溶剂是指配制和稀释待测抑制剂所用的溶剂。
b.各孔加入COX-2Probe 5微升。
c.各孔快速加入COX-2 Substrate工作液5微升，混匀。注：加入COX-2 Substrate工作液后反应即会开始，如果孔数较多，可以在低温操作或使用排枪操作以减小各孔间加入COX-2 Substrate工作液的时间差而导致的误差，混匀也可以在培养板振荡器上进行。
d.37℃避光孵育5分钟后进行荧光测定。激发波长为560nm，发射波长为590nm。当荧光读数偏低时，也可适当延长孵育时间至10-20分钟。
(4)计算：
a.计算每个样品孔和空白对照孔的平均荧光值，可分别记录为RFU空白对照、RFU100％酶活性对照、RFU阳性抑制剂对照和RFU样品。RFU，Relative Fluorescence Unit。
b.计算每个样品的抑制百分率。计算公式如下：
抑制率(％)＝(RFU100％酶活性对照-RFU样品)/(RFU100％酶活性对照-RFU空白对照)×100％
COX-2抑制率测定结果如表3所示：
表3浓度为200μg/mL的样品COX-2抑制率
从表3的实验结果可以得出，五味子和沙棘的超临界提取物对COX-2均具有抑制效果，其中实施例1-3相比于对比例1-4的抑制效果更好，特别是实施例1，明显地优于对比例1-5。
实验例4
采用痤疮丙酸杆菌诱导HaCaT细胞炎症因子高表达模型，检测不同工艺下五味子-沙棘组合物的对炎症因子IL-1β分泌的影响，研究其抗炎功效操作如下：
1.痤疮丙酸杆菌诱导HaCaT细胞炎症因子高表达模型
(1)取出处于对数生长期的HaCaT细胞，配制细胞浓度1×105cells/mL，96孔板每孔接入200μL细胞液，置于培养箱37℃，5％CO2环境中培养12h至细胞贴壁。
(2)配制样品培养基：将样品用无血清培养基稀释至1.00％浓度。
(3)痤疮杆菌配制：用复苏3代后的新鲜痤疮杆菌，用离心机离心后，除去上清液，用PBS稀释痤疮杆菌，然后用酶标仪测OD600nm＝0.5(2×108CFU/mL)的菌浓度，现用现配。
(4)当HaCaT细胞培养贴壁后，吸去培养液后，用PBS清洗两次，设置空白组、模型组及样品组，按照以下分组加入培养基孵育6h：
空白组，加入200μL无血清培养基。
模型组，加入200μL无血清培养基。
样品组，加入200μL不同样品培养基。
(5)孵育4h后对模型组和样品组进行痤疮杆菌刺激(刺激剂量为10μL/孔)。
(6)将96孔板置于培养箱37℃，5％CO2环境中培养18h，收集细胞上清液，用ELISA试剂盒进行IL-1β含量检测。
2.IL-1β含量测定结果
表4实施例1-3与对比例1-5的提取物对IL-1β分泌的影响
注：##表示与空白相比，p<0.01；**表示与模型组相比，p<0.01；*表示与模型组相比，p<0.05
根据表4的测定结果可以发现，相比于模型组，五味子和沙棘的超临界提取物对IL-1β分泌均具有抑制效果，其中实施例1-3的抑制程度更大，在实施例1-3的作用下，IL-1β含量更接近空白组。
以上所述仅为本发明的优选实施例而已，并不用于限制本发明，对于本领域的技术人员来说，本发明可以有各种更改和变化。凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (10)
1.一种五味子和沙棘组合物的超临界CO2提取方法，其特征在于，包括将五味子和沙棘粉末混合后进行超临界CO2提取处理，得到五味子-沙棘超临界提取物；
所述五味子和沙棘的投料比为(1-3)：(1-3)。
2.根据权利要求1所述的五味子和沙棘组合物的超临界CO2提取方法，其特征在于，所述超临界CO2提取处理的条件为：提取压力为150-250bar，提取温度为35-45℃，提取时间为80-100min，CO2的流速为4-6mL/min；
优选地，所述提取时间为：动态提取10min→静态提取10min→动态提取10min，循环3次。
3.根据权利要求2所述的五味子和沙棘组合物的超临界CO2提取方法，其特征在于，所述超临界CO2提取处理的夹带剂为无水乙醇，
优选地，所述夹带剂的流速为0.5-2mL/min；
优选地，所述夹带剂与CO2的流量比为1:(4-6)。
4.根据权利要求1所述的五味子和沙棘组合物的超临界CO2提取方法，其特征在于，所述五味子和沙棘粉末是通过粉碎处理后获得的20-50目粉末。
5.一种五味子-沙棘超临界提取物，其特征在于，所述五味子-沙棘超临界提取物通过权利要求1-4任一项所述的五味子和沙棘组合物的超临界CO2提取方法制备得到。
6.根据权利要求5所述的五味子-沙棘超临界提取物，其特征在于，所述五味子-沙棘超临界提取物中包括棕榈酸、硬脂酸、油酸、亚油酸和亚麻酸；
优选地，所述五味子-沙棘超临界提取物中棕榈酸≥28.91mg/g，硬脂酸≥8.87mg/g，油酸≥54.90mg/g，亚油酸≥314.36mg/g，亚麻酸≥79.35mg/g。
7.如权利要求5或6所述的五味子-沙棘超临界提取物在制备抗炎产品中的应用。
8.如权利要求5或6所述的五味子-沙棘超临界提取物在制备COX-2抑制剂中的应用。
9.如权利要求5或6所述的五味子-沙棘超临界提取物在制备抑制痤疮丙酸杆菌诱导的炎症的产品中的应用。
10.如权利要求5或6所述的五味子-沙棘超临界提取物在制备抑制炎症因子IL-1β分泌的产品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310180573.6A CN116035983B (zh) | 2023-02-15 | 2023-02-15 | 五味子和沙棘组合物的超临界co2提取方法及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310180573.6A CN116035983B (zh) | 2023-02-15 | 2023-02-15 | 五味子和沙棘组合物的超临界co2提取方法及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116035983A true CN116035983A (zh) | 2023-05-02 |
| CN116035983B CN116035983B (zh) | 2024-10-08 |
Family
ID=86122045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310180573.6A Active CN116035983B (zh) | 2023-02-15 | 2023-02-15 | 五味子和沙棘组合物的超临界co2提取方法及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116035983B (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102994217A (zh) * | 2012-11-15 | 2013-03-27 | 山西五台山沙棘制品有限公司 | 一种超临界co2萃取沙棘籽的方法 |
| CN103598413A (zh) * | 2013-11-05 | 2014-02-26 | 敦化市长白山绿色禽产品科技开发有限公司 | 一种沙棘果、五味子复合禽饲料添加剂 |
| CN104274498A (zh) * | 2014-09-18 | 2015-01-14 | 开平健之源保健食品有限公司 | 一种高效抗肿瘤灵芝提取物及其制备方法 |
| KR20160012273A (ko) * | 2014-07-23 | 2016-02-03 | 서동욱 | 저온숙성추출법에 의한 비타민나무잎 추출물을 추출하는 방법 및 이를 이용한 항염 효과가 우수한 화장료 조성물 |
| CN109247461A (zh) * | 2017-07-16 | 2019-01-22 | 郑州国手生物科技有限公司 | 一种安神促眠美容果醋饮品 |
| CN109864231A (zh) * | 2017-12-05 | 2019-06-11 | 李新华 | 百合五味子美容醋饮品的制备工艺 |
-
2023
- 2023-02-15 CN CN202310180573.6A patent/CN116035983B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102994217A (zh) * | 2012-11-15 | 2013-03-27 | 山西五台山沙棘制品有限公司 | 一种超临界co2萃取沙棘籽的方法 |
| CN103598413A (zh) * | 2013-11-05 | 2014-02-26 | 敦化市长白山绿色禽产品科技开发有限公司 | 一种沙棘果、五味子复合禽饲料添加剂 |
| KR20160012273A (ko) * | 2014-07-23 | 2016-02-03 | 서동욱 | 저온숙성추출법에 의한 비타민나무잎 추출물을 추출하는 방법 및 이를 이용한 항염 효과가 우수한 화장료 조성물 |
| CN104274498A (zh) * | 2014-09-18 | 2015-01-14 | 开平健之源保健食品有限公司 | 一种高效抗肿瘤灵芝提取物及其制备方法 |
| CN109247461A (zh) * | 2017-07-16 | 2019-01-22 | 郑州国手生物科技有限公司 | 一种安神促眠美容果醋饮品 |
| CN109864231A (zh) * | 2017-12-05 | 2019-06-11 | 李新华 | 百合五味子美容醋饮品的制备工艺 |
Non-Patent Citations (3)
| Title |
|---|
| MAYYA RAZGONOVA等: ""Rapid Mass Spectrometric Study of a SupercriticalCO2-extract from Woody LianaSchisandra chinensisby HPLC-SPD-ESI-MS/MS"", 《MOLECULES》, no. 25, 10 June 2020 (2020-06-10), pages 1 - 10 * |
| 李丽等: ""HPLC 测定五味子中 3 种有机酸的含量"", 《中国中药杂志》, vol. 36, no. 23, 31 December 2011 (2011-12-31), pages 3286 - 3289 * |
| 李丽等: ""五味子酸性组分的主要物质基础与生物活性研究"", 《中国实验方剂学杂志》, vol. 20, no. 6, 31 March 2014 (2014-03-31), pages 70 - 73 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116035983B (zh) | 2024-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Subhasree et al. | Evaluation of antioxidant potential in selected green leafy vegetables | |
| Hossain et al. | A study on the total phenols content and antioxidant activity of essential oil and different solvent extracts of endemic plant Merremia borneensis | |
| Tung et al. | Antioxidant activities of natural phenolic compounds from Acacia confusa bark | |
| El-Soud et al. | Ability of ellagic acid to alleviate osmotic stress on chickpea seedlings | |
| Saha et al. | Evaluation of antioxidant and nitric oxide inhibitory activities of selected Malaysian medicinal plants | |
| Kumbhare et al. | Estimation of total phenolic content, cytotoxicity and in–vitro antioxidant activity of stem bark of Moringa oleifera | |
| Korekar et al. | Phenolic content and antioxidant capacity of various solvent extracts from seabuckthorn (Hippophae rhamnoides L.) fruit pulp, seeds, leaves and stem bark | |
| Yin et al. | Antioxidant and antidiabetic activities of extracts from Cirsium japonicum roots | |
| Arimboor et al. | Tetrahydroamentoflavone (THA) from Semecarpus anacardium as a potent inhibitor of xanthine oxidase | |
| Rafiquzzaman et al. | Phytochemical Composition and Antioxidant Activity of Edible Red Alga H ypnea musciformis from B angladesh | |
| Yang et al. | Antioxidative activities and components of Gardenia jasminoides | |
| Kim et al. | Antioxidant activity of a hydrothermal extract from watermelons | |
| Kandasamy et al. | Polyphenolic profile and antioxidant properties of rhizome of commercial banana cultivars grown in India | |
| Yao et al. | Different harvest seasons modify bioactive compounds and antioxidant activities of Pyrola incarnata | |
| Malekpoor et al. | Effect of jasmonic acid on total phenolic content and antioxidant activity of extract from the green and purple landraces of sweet basil | |
| Choudhury et al. | Development of single node cutting propagation techniques and evaluation of antioxidant activity of Curcuma aeruginosa Roxburgh rhizome | |
| Jalali Mousavi et al. | Antioxidant activity of purslane (Portulaca oleracea L.) seed hydro-alcoholic extract on the stability of soybean oil | |
| Araruna et al. | Anti-inflammatory activities of triterpene lactones from Lactuca sativa | |
| Lin et al. | Antioxidant potency of phenolic phytochemicals from the root extract of Acacia confusa | |
| Wang et al. | Antioxidant activity and inhibition effect on the growth of human colon carcinoma (HT-29) cells of esculetin from Cortex Fraxini | |
| Akhila et al. | Quantification of seed oil and evaluation of antioxidant properties in the wild and cultivated species of Sesamum L.(Pedaliaceae) | |
| Peerakam et al. | Chemical profiling revealed a dominant compound trans-anethole and biological evaluation of an edible plant Clausena harmandiana containing essential oil | |
| CN116035983B (zh) | 五味子和沙棘组合物的超临界co2提取方法及其应用 | |
| CN106667833B (zh) | 油茶种皮提取物及其制备方法和应用 | |
| Yoon et al. | Antioxidant activities and xanthine oxidase inhibitory effects of hot-water extracts from fruits of Elaeagnus multiflora Thunb. in maturity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |